{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:41Z","timestamp":1789419821825,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,25]]},"DOI":"10.7759\/cureus.67729","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T14:05:45Z","timestamp":1724594745000},"source":"Crossref","is-referenced-by-count":5,"title":["Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital"],"prefix":"10.7759","author":[{"given":"Marco Aurelio","family":"Ramirez Huaranga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Angel","family":"Calvo Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Velasco Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Martin de la Sierra Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jimenez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lopez Menchero Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Castro Corredor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Gonzalez Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka K","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004, 5:253. 10.1186\/gb-2004-5-12-253","journal-title":"Genome Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark JD","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014, 57:5023-38. 10.1021\/jm401490p","journal-title":"J Med Chem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2018.10.020","article-title":"JAK-STAT inhibitors for the treatment of immunomediated diseases","volume":"152","author":"Serra L\u00f3pez-Matencio JM","year":"2019","unstructured":"Serra L\u00f3pez-Matencio JM, Morell Baladr\u00f3n A, Casta\u00f1eda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Med Clin (Barc). 2019, 152:353-60. 10.1016\/j.medcli.2018.10.020","journal-title":"Med Clin (Barc)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop KL","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017, 13:234-43. 10.1038\/nrrheum.2017.23","journal-title":"Nat Rev Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1049-3","article-title":"Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis","volume":"18","author":"Genovese MC","year":"2016","unstructured":"Genovese MC, van Vollenhoven RF, Wilkinson B, et al.. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther. 2016, 18:145. 10.1186\/s13075-016-1049-3","journal-title":"Arthritis Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp KA","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, et al.. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016, 74:841-50. 10.1016\/j.jaad.2016.01.013","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone EC","year":"2017","unstructured":"Keystone EC, Taylor PC, Tanaka Y, et al.. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017, 76:1853-61. 10.1136\/annrheumdis-2017-211259","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados M","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, et al.. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017, 76:88-95. 10.1136\/annrheumdis-2016-210094","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese MC","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, et al.. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016, 68:2857-66. 10.1002\/art.39808","journal-title":"Arthritis Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer JM","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS, et al.. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016, 68:2867-77. 10.1002\/art.39801","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1872312810666151223103353","article-title":"Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions","volume":"10","author":"Namour F","year":"2016","unstructured":"Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016, 10:38-48. 10.2174\/1872312810666151223103353","journal-title":"Drug Metab Lett"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh A","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, et al.. Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017, 76:1009-19. 10.1136\/annrheumdis-2016-210105","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2021.08.004","article-title":"Real-world effectiveness and safety of Jak inhibitors in rheumatoid arthritis: a single-centre study","volume":"18","author":"Gonz\u00e1lez Mazar\u00edo R","year":"2022","unstructured":"Gonz\u00e1lez Mazar\u00edo R, Frag\u00edo Gil JJ, Ivorra Cort\u00e9s J, et al.. Real-world effectiveness and safety of Jak inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin (Engl Ed). 2022, 18:523-30. 10.1016\/j.reumae.2021.08.004","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al.. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009, 68:777-83. 10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor W","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006, 54:2665-73. 10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S322086","article-title":"Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis","volume":"13","author":"Bertoldi I","year":"2021","unstructured":"Bertoldi I, Caporali R. Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis. Open Access Rheumatol. 2021, 13:221-37. 10.2147\/OARRR.S322086","journal-title":"Open Access Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06836-w","article-title":"ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in central Italy","volume":"43","author":"D'Alessandro F","year":"2024","unstructured":"D'Alessandro F, Cazzato M, Laurino E, et al.. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in central Italy. Clin Rheumatol. 2024, 43:657-65. 10.1007\/s10067-023-06836-w","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00423-8","article-title":"Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (the ORBIT-RA study)","volume":"9","author":"Hern\u00e1ndez-Cruz B","year":"2022","unstructured":"Hern\u00e1ndez-Cruz B, Rosas J, D\u00edaz-Torn\u00e9 C, et al.. Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (the ORBIT-RA study). Rheumatol Ther. 2022, 9:589-608. 10.1007\/s40744-021-00423-8","journal-title":"Rheumatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00591-9","article-title":"Systematic literature review of real-world evidence on baricitinib for the treatment of rheumatoid arthritis","volume":"10","author":"Hern\u00e1ndez-Cruz B","year":"2023","unstructured":"Hern\u00e1ndez-Cruz B, Kiltz U, Avouac J, et al.. Systematic literature review of real-world evidence on baricitinib for the treatment of rheumatoid arthritis. Rheumatol Ther. 2023, 10:1417-57. 10.1007\/s40744-023-00591-9","journal-title":"Rheumatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00651-8","article-title":"Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational close-up study","volume":"11","author":"Bessette L","year":"2024","unstructured":"Bessette L, Chan J, Chow A, et al.. Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational close-up study. Rheumatol Ther. 2024, 11:563-82. 10.1007\/s40744-024-00651-8","journal-title":"Rheumatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/k78ug3","article-title":"Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience","volume":"42","author":"La Barbera L","year":"2024","unstructured":"La Barbera L, Rizzo C, Camarda F, et al.. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience. Clin Exp Rheumatol. 2024, 42:991-8. 10.55563\/clinexprheumatol\/k78ug3","journal-title":"Clin Exp Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061821","article-title":"Real-life comparison of four JAK inhibitors in rheumatoid arthritis (ELECTRA-I study)","volume":"13","author":"Benucci M","year":"2024","unstructured":"Benucci M, Li Gobbi F, Damiani A, et al.. Real-life comparison of four JAK inhibitors in rheumatoid arthritis (ELECTRA-I study)\r\n. J Clin Med. 2024, 13:1821. 10.3390\/jcm13061821","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0145","article-title":"Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study","author":"Lanzillotta M","year":"2023","unstructured":"Lanzillotta M, Boffini N, Barone E, et al.. Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study. J Rheumatol. 2023, 10.3899\/jrheum.2023-0145","journal-title":"J Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14570","article-title":"Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real-world retrospective analysis from India","volume":"26","author":"Phatak S","year":"2023","unstructured":"Phatak S, Khenat A, Malandkar M, Amin S. Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real-world retrospective analysis from India. Int J Rheum Dis. 2023, 26:487-92. 10.1111\/1756-185X.14570","journal-title":"Int J Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002069","article-title":"Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: a real-world clinical context multicenter study","volume":"30","author":"Goswami RP","year":"2024","unstructured":"Goswami RP, Sinha D, Chatterjee M, Bhadu D, Das S. Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: a real-world clinical context multicenter study. J Clin Rheumatol. 2024, 30:e108-14. 10.1097\/RHU.0000000000002069","journal-title":"J Clin Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02084-7","article-title":"Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database","volume":"39","author":"Mease PJ","year":"2022","unstructured":"Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A. Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database. Adv Ther. 2022, 39:2932-45. 10.1007\/s12325-022-02084-7","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06930-7","article-title":"Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia","volume":"43","author":"Littlejohn G","year":"2024","unstructured":"Littlejohn G, Leadbetter J, Butcher BE, et al.. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia. Clin Rheumatol. 2024, 43:1579-89. 10.1007\/s10067-024-06930-7","journal-title":"Clin Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286362-real-world-experience-with-janus-kinase-inhibitors-in-immune-mediated-diseases-clinical-experience-of-a-university-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T14:05:49Z","timestamp":1724594749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286362-real-world-experience-with-janus-kinase-inhibitors-in-immune-mediated-diseases-clinical-experience-of-a-university-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.67729","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}